Biogenetics is a biopharmaceutical company devoted to provide innovative therapies to people bravely fighting cancer and rare disease. We see new possibilities to responsibly develop and commercialize first-in-class treatments where others may not. Our mission is to improve patient lives by identifying and developing novel treatments that help people live better and longer.
Biogenetics is dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products including in clinical stage as well as preclinical stage that have the potential to address a broad range of therapeutic effects with high unmet medical needs.
Relationships are vital to the success of our business, and we are committed to being a trusted partner to the biopharmaceutical industry.
Biogenetics signed license agreement
with Aslan for ASLAN003.
Biogenetics’s subsidiary BioCast signed technology transfer agreement with KyungHee Univ. for T-type calcium channel blocker.
Biogenetics signed license agreement with Aslan for varlitinib.
Biogenetic's subsidiary BioCast made a BCMA CAR-T Technology Transfer Agreement with Shenzhen Pregene Biopharma.
Biogenetic's subsidiary BioCast obtained the Certificate of Research and Development Center from KOITA.
Contracted Collaborative research and profit-sharing agreement for targeted anti-colorectal cancer agent with WMBio
Appointed JooHoon Ahn as a representative director (CEO) at the board meeting and declared the company vision and mission for Pharma & Bio field
Changed company name as Biogenetics Co., Ltd
Established a 100% subsidiary corporation in China- UNIDUS (ZHANGJIAGANG) Rubber Products Co., Ltd
Listed on KOSDAQ(Korea Securities Dealers Association Automated Quotations)
Changed company name as UNIDUS Corporation
Established a new factory in Jeungpyoung
Established as Seohung Industrial Co.,Ltd in Cheongju, Korea